基石药业－Ｂ(02616.HK) 公布，nofazinlimab治疗肝细胞癌的国际多中心III期研究最终分析结果显示，nofazinlimab联合仑伐替尼对比安慰剂联合仑伐替尼，总生存期呈现出明显的临床获益趋势，尽管未达到统计学显著性，但仍显示出切实的患者获益。此外，nofazinlimab安全性良好，与既往研究结果以及已上市的抗 PD-(L)1 抗体安全性特征一致，未观察到新的安全性信号。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.